No Evidence of Tirzepatide Causing Increased Spasticity in MS
There is no documented evidence that tirzepatide (Zepbound) increases spasticity in patients with multiple sclerosis. Based on available data, tirzepatide can be safely used in MS patients when indicated for obesity or type 2 diabetes, with standard monitoring for its known side effects.
Evidence Review
What We Know About Tirzepatide in MS Patients
A recent cross-sectional survey of 4,181 MS patients found that 7.4% had ever used GLP-1 receptor agonists (including tirzepatide), with 5.5% currently using them 1. Importantly, no reports of increased spasticity or worsening neurological symptoms were documented in this MS population.
Known Side Effects of Tirzepatide
The established adverse effects of tirzepatide are primarily gastrointestinal 2, 3:
- Nausea (25% of patients)
- Vomiting and diarrhea (up to 10%)
- Heartburn (as reported in a spinal cord injury case) 4
- Increased risk of gallbladder/biliary disease 2
- Modest increase in heart rate 3
Spasticity is not listed among the known adverse effects of tirzepatide in any guideline or drug safety data.
Clinical Reasoning
Why This Question Arises
MS patients with spasticity may experience symptom fluctuations due to:
- Dehydration (which tirzepatide can cause through GI side effects) 3
- Weight loss altering body mechanics and muscle tone
- Concurrent MS disease activity unrelated to medication
Practical Management Approach
If an MS patient on tirzepatide reports increased spasticity:
Rule out dehydration first - GI side effects (nausea, vomiting, diarrhea) can lead to dehydration, which may worsen existing spasticity 3
- Ensure adequate fluid intake
- Monitor for signs of volume depletion
Assess for MS disease activity - New or worsening spasticity may indicate disease progression rather than medication effect
- Consider MRI if clinically indicated 5
- Evaluate for new neurological symptoms
Continue standard spasticity management 6:
- Antispastic positioning and range of motion exercises
- Consider tizanidine, dantrolene, or oral baclofen if spasticity causes pain or functional impairment
- Botulinum toxin for focal spasticity
Maintain tirzepatide if indicated - The metabolic and cardiovascular benefits likely outweigh theoretical concerns, especially given:
Important Caveats
- Correlation is not causation - Temporal association between starting tirzepatide and worsening spasticity does not establish causality
- MS is a progressive disease - Symptom fluctuations occur independently of medications
- Dehydration is the most likely culprit if spasticity worsens after starting tirzepatide, not a direct drug effect on the nervous system
The evidence strongly suggests that any perceived increase in spasticity is more likely related to dehydration from GI side effects or coincidental MS disease activity rather than a direct neurotoxic effect of tirzepatide.